Ladis V - Search Results

1

Cardiac related death in thalassaemia major: time trend and risk factors in a large Greek Unit.

Chouliaras G, Yiannoutsos CT, Berdoukas V, Ladis V. Chouliaras G, et al. Among authors: ladis v. Eur J Haematol. 2009 May;82(5):381-7. doi: 10.1111/j.1600-0609.2009.01218.x. Epub 2009 Jan 9. Eur J Haematol. 2009. PMID: 19141117

2

Relation of chelation regimes to cardiac mortality and morbidity in patients with thalassaemia major: an observational study from a large Greek Unit.

Ladis V, Chouliaras G, Berdoukas V, Moraitis P, Zannikos K, Berdoussi E, Kattamis C. Ladis V, et al. Eur J Haematol. 2010 Oct;85(4):335-44. doi: 10.1111/j.1600-0609.2010.01491.x. Epub 2010 Aug 30. Eur J Haematol. 2010. PMID: 20561034 Free PMC article.

3

Evaluation of liver fibrosis in patients with thalassemia: the important role of hyaluronic acid.

Papastamataki M, Delaporta P, Premetis E, Kattamis A, Ladis V, Papassotiriou I. Papastamataki M, et al. Among authors: ladis v. Blood Cells Mol Dis. 2010 Oct 15;45(3):215-8. doi: 10.1016/j.bcmd.2010.06.002. Epub 2010 Jul 6. Blood Cells Mol Dis. 2010. PMID: 20605573

4

The efficacy of iron chelator regimes in reducing cardiac and hepatic iron in patients with thalassaemia major: a clinical observational study.

Berdoukas V, Chouliaras G, Moraitis P, Zannikos K, Berdoussi E, Ladis V. Berdoukas V, et al. Among authors: ladis v. J Cardiovasc Magn Reson. 2009 Jun 28;11(1):20. doi: 10.1186/1532-429X-11-20. J Cardiovasc Magn Reson. 2009. PMID: 19558722 Free PMC article.

5

Erythroid bone marrow activity and red cell hemoglobinization in iron sufficient beta-thalassemia heterozygotes as reflected by soluble transferrin receptor and reticulocyte hemoglobin in content. Correlation with genotypes and Hb A(2) levels.

Skarmoutsou C, Papassotiriou I, Traeger-Synodinos J, Stamou H, Ladis V, Metaxotou-Mavrommati A, Stamoulakatou A, Kanavakis E. Skarmoutsou C, et al. Among authors: ladis v. Haematologica. 2003 Jun;88(6):631-6. Haematologica. 2003. PMID: 12801838

6

Iron chelation treatment with combined therapy with deferiprone and deferioxamine: a 12-month trial.

Kattamis A, Ladis V, Berdousi H, Kelekis NL, Alexopoulou E, Papasotiriou I, Drakaki K, Kaloumenou I, Galani A, Kattamis C. Kattamis A, et al. Among authors: ladis v. Blood Cells Mol Dis. 2006 Jan-Feb;36(1):21-5. doi: 10.1016/j.bcmd.2005.11.002. Epub 2006 Jan 4. Blood Cells Mol Dis. 2006. PMID: 16386928 Clinical Trial.

7

Impaired oxygen kinetics in beta-thalassaemia major patients.

Vasileiadis I, Roditis P, Dimopoulos S, Ladis V, Pangalis G, Aessopos A, Nanas S. Vasileiadis I, et al. Among authors: ladis v. Acta Physiol (Oxf). 2009 Jul;196(3):357-63. doi: 10.1111/j.1748-1716.2008.01937.x. Epub 2008 Nov 27. Acta Physiol (Oxf). 2009. PMID: 19040710 Clinical Trial.

8

The impact of neocyte transfusion in the management of thalassaemia.

Spanos T, Ladis V, Palamidou F, Papassotiriou I, Banagi A, Premetis E, Kattamis C. Spanos T, et al. Among authors: ladis v. Vox Sang. 1996;70(4):217-23. doi: 10.1111/j.1423-0410.1996.tb01330.x. Vox Sang. 1996. PMID: 9123927 Clinical Trial.

9

Glucose disturbances and regulation with glibenclamide in thalassemia.

Ladis V, Theodorides C, Palamidou F, Frissiras S, Berdousi H, Kattamis C. Ladis V, et al. J Pediatr Endocrinol Metab. 1998;11 Suppl 3:871-8. J Pediatr Endocrinol Metab. 1998. PMID: 10091160 Clinical Trial.

10

Growth and management of short stature in thalassaemia major.

Theodoridis C, Ladis V, Papatheodorou A, Berdousi H, Palamidou F, Evagelopoulou C, Athanassaki K, Konstantoura O, Kattamis C. Theodoridis C, et al. Among authors: ladis v. J Pediatr Endocrinol Metab. 1998;11 Suppl 3:835-44. J Pediatr Endocrinol Metab. 1998. PMID: 10091154

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results